Objective To assess racial/ethnic differences in the use of biologic disease‐modifying
antirheumatic drugs (DMARDs) among California Medicaid (Medi‐Cal) rheumatoid arthritis …

Objective Disease‐modifying antirheumatic drugs (DMARDs) are recommended for virtually
all patients with rheumatoid arthritis (RA). We investigated the use of DMARDs in patients …

Background In the United States, there is racial/ethnic disparity in the care of rheumatoid
arthritis (RA), yet there are limited data regarding the impact of varied health care systems …

Introduction Numerous studies across different health systems have documented that many
patients with rheumatoid arthritis (RA) do not receive disease-modifying anti-rheumatic …

Objective Use of nonbiologic disease‐modifying antirheumatic drugs (DMARDs) and/or
biologic DMARDs is generally recommended to improve the prognosis of patients with …

Background Biologic disease-modifying antirheumatic drugs (DMARDs) are increasingly
used for rheumatoid arthritis (RA) treatment. However, little is known based on contemporary …

Objective We examined the treatment patterns among adults with rheumatoid arthritis (RA)
and identified factors influencing access to traditional and biological disease modifying …

Abstract Objective The National Committee on Quality Assurance has determined that all
patients with rheumatoid arthritis (RA) should be treated with disease‐modifying …

Objective To determine racial/ethnic differences in the use of conventional synthetic or
biologic disease-modifying anti-rheumatic drugs (csDMARDs or bDMARDs, respectively) …

Introduction Disease-modifying antirheumatic drugs (DMARDs) have become the treatment
standard for patients with rheumatoid arthritis (RA). Although several general-population …